What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis
Objectives A treat-to-target (T2T) strategy has been shown to be superior to usual care in rheumatoid arthritis (RA), but the optimal target remains unknown. Targets are based on a disease activity measure (eg, Disease Activity Score-28 (DAS28), Simplified Disease Activity Indices/Clinical Disease A...
Main Authors: | Daniel Aletaha, Alfons A den Broeder, Paco M J Welsing, Janneke Tekstra, P Verschueren, Marianne A Messelink, Florine E Marinelli, Edwin Michgels |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-04-01
|
Series: | RMD Open |
Online Access: | https://rmdopen.bmj.com/content/9/2/e003196.full |
Similar Items
-
Concomitant prednisone may alleviate methotrexate side-effects in rheumatoid arthritis patients
by: Matthijs S. van der Leeuw, et al.
Published: (2023-05-01) -
Prediction of response to anti-TNF treatment using laboratory biomarkers in patients with rheumatoid arthritis: a systematic review
by: Alfons A den Broeder, et al.
Published: (2022-12-01) -
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study
by: Daniel Aletaha, et al.
Published: (2023-03-01) -
Remission definitions guiding immunosuppressive therapy in rheumatoid arthritis: which is best fitted for the purpose?
by: Désirée van der Heijde, et al.
Published: (2024-02-01) -
Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study)
by: Céleste J.T. van der Togt, et al.
Published: (2022-12-01)